Jump to content

Recommended Posts

Here is the weekly clip report:

The ASCO Post
“Stand Up To Cancer Launches ‘Cancer Interception’ Teams to Detect and Treat Cancer at Earliest Stages”
http://www.ascopost.com/issues/november-25-2017/stand-up-to-cancer-launches-cancer-interception-teams-to-detect-and-treat-cancer-at-earliest-stages/

Stanford Medicine News Center
“Stanford Scientists among Those Funded by Stand Up To Cancer”
https://med.stanford.edu/news/all-news/2017/11/stanford-scientists-among-those-funded-by-stand-up-to-cancer.html

Immuno-Oncology News
“Imfinzi Increases Time for Non-Small Cell Lung Cancer to Progress, Phase 3 Trial Shows”
https://immuno-oncologynews.com/2017/11/28/phase-3-trial-shows-imfinzi-lengthens-time-for-non-small-cell-lung-cancer-to-return/

Targeted Oncology
“Ahead of NSCLC Approval Decision, FDA Now Weighing Durvalumab Data in NEJM”
http://www.targetedonc.com/news/ahead-of-nsclc-approval-decision-fda-now-weighing-durvalumab-data-in-nejm

OncLive
“Immunotherapy to Have Emerging Role in Squamous Cell Lung Cancer”
http://www.onclive.com/web-exclusives/immunotherapy-to-have-emerging-role-in-squamous-cell-lung-cancer

Business Wire
“Impassioned Lung Cancer Survivors Join Your Cancer Game Plan, Merck to Advocate for Others Facing This Highly Stigmatized Disease”
http://www.businesswire.com/news/home/20171129005025/en/Impassioned-Lung-Cancer-Survivors-Join-Cancer-Game

The Baltimore Sun
“Life After Lung Cancer: How One Survivor is Fighting for Others”
http://www.baltimoresun.com/bp/blt-ara-31849-life-after-lung-cancer-how-one-survivor-is-fighting-for-others-20171129-adstory.html

National Press Club
“Life After Cancer: Addressing Survivorship in Cancer Care”
http://www.press.org/events/life-after-cancer-addressing-survivorship-cancer-care
Markets Insider
“Biocept and UC San Diego Medical Center Announce Clinical Study Collaboration to Demonstrate Utility of Biocept’s Liquid Biopsy Test in Immunotherapy”
http://markets.businessinsider.com/news/stocks/Biocept-and-UC-San-Diego-Medical-Center-Announce-Clinical-Study-Collaboration-to-Demonstrate-Utility-of-Biocept-s-Liquid-Biopsy-Test-in-Immunotherapy-1009786790

Medical Xpress
“Two-Drug Combination May Boost Immunotherapy Response in Lung Cancer Patients”
https://medicalxpress.com/news/2017-11-two-drug-combination-boost-immunotherapy-responses.html

Reuters
“FDA Aims to Approve More Drugs Based on Early Clinical Data”
https://www.reuters.com/article/us-fda-hearing-testimony/fda-aims-to-approve-more-drugs-based-on-early-clinical-data-idUSKBN1DU2DS

Healio
“Eight Important Updates in Lung Cancer”
https://www.healio.com/hematology-oncology/lung-cancer/news/online/{56102e9b-63d2-4eea-8859-01b452dbe2b3}/eight-important-updates-in-lung-cancer

Investor’s Business Daily
“This Biotech Launched to a Record High on Cancer Test Approval”
https://www.investors.com/news/technology/this-biotech-launched-to-a-record-high-on-cancer-test-approval/

DOD Congressionally Directed Medical Research Programs
“Melissa Crouse – Lung Cancer Warrior, Mentor and Advocate”
http://cdmrp.army.mil/cwg/stories/2017/melissa_crouse_profile

Business Wire
“FDA Approves Foundation Medicine’s FoundationOne Cdx, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics”
http://www.businesswire.com/news/home/20171130006320/en/FDA-Approves-Foundation-Medicine’s-FoundationOne-CDx™-Comprehensive

Markets Insider
“Advocates Reveal Cancer Survivorship Challenges and Resources During National Comprehensive Cancer Network’s Patient Advocacy Summit”
http://markets.businessinsider.com/news/stocks/Advocates-Reveal-Cancer-Survivorship-Challenges-and-Resources-during-National-Comprehensive-Cancer-Network-s-Patient-Advocacy-Summit-1010204005

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
Sign in to follow this  

×